| Literature DB >> 18724071 |
Han Hsi Wong1, Nicholas R Lemoine.
Abstract
Pancreatic cancer is a lethal disease and notoriously difficult to treat. Only a small proportion is curative by surgical resection, whilst standard chemotherapy for patients with advanced disease has only modest effect with substantial toxicity. Clearly there is a need for the continual development of novel therapeutic agents to improve the current situation. Improvement of our understanding of the disease has generated a large number of studies on biological approaches targeting the molecular abnormalities of pancreatic cancer, including gene therapy and signal transduction inhibition, antiangiogenic and matrix metalloproteinase inhibition, oncolytic viral therapy and immunotherapy. This article provides a review of these approaches, both investigated in the laboratories and in subsequent clinical trials. Copyright 2008 S. Karger AG, Basel.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18724071 PMCID: PMC2882228 DOI: 10.1159/000151536
Source DB: PubMed Journal: Pancreatology ISSN: 1424-3903 Impact factor: 3.996